RQM+ Appoints Denise Wocko as Head of Global Client Portfolio Management
RQM+, the world’s leading MedTech service provider, today announced the appointment of Denise Wocko as head of global client portfolio management. In her new role, Wocko will work directly with RQM+ clients to provide seamless access to its integrated services, including reimbursement, clinical trials, lab testing and regulatory consulting, that support all phases of the product lifecycle.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230406005546/en/
Denise Wocko, RQM+ Head of Global Client Portfolio Management (Photo: Business Wire)
“We have an incredible opportunity to reduce the risk of clients who have trusted us with managing their regulatory and quality processes for 40 years by helping them navigate each critical step of their product’s journey,” said Wocko. “Our deep expertise in global regulatory consulting – with the largest global team of regulatory experts and former FDA, MHRA and notified body professionals – differentiates us and serves as the foundation for our expanded services. Our clients have asked us to integrate regulatory, clinical, biocompatibility and market access disciplines to give them efficient, end-to-end support. My goal is to make RQM+ the MedTech partner of choice by removing the challenges of a fragmented service landscape that manufacturers are dealing with today.”
Based in Geneva, Wocko has held commercial leadership roles at both niche and large organizations where she worked closely with clients to develop strategic partnerships that meet their objectives. Her experience spans the MedTech, pharmaceutical and biotech industries, as well as with the contract research organizations (CROs) that serve them.
About RQM+
RQM+ is the leading MedTech service provider with the world’s largest global team of regulatory and quality experts. Building upon 40 years of regulatory expertise, we also provide comprehensive clinical trial, lab and reimbursement services – reducing risk throughout the entire product lifecycle for medical devices, digital therapeutics and diagnostics. With more former FDA, MHRA and notified body regulators than any other firm, the RQM+ team has deep expertise in all clinical specialties. We currently works for 19 of the top 20 medical device manufacturers and seven of the top 10 IVD companies. For more information, visit RQMplus.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230406005546/en/
Contact information
Media: Rob Pepper, +1.301.254.6100, rpepper@rqmplus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Norton Motorcycles Launches Bold New Product and Brand Resurgence at EICMA 20254.11.2025 15:38:00 EET | Press release
Norton Motorcycles has unveiled its Resurgence strategy at EICMA, a long-term approach underpinned by the substantial investment by TVS Motor Company (TVS) since it acquired Norton Motorcycles in April 2020. Five years in the making, this rebirth is based on a cascade of innovative new models defined by Norton’s core attributes – a combination of Design, Dynamics and Detail that will create the world’s most desirable motorcycles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104808619/en/ L to R: Sharad Mohan Mishra, President, Group Strategy, TVSM; Sudarshan Venu, Chairman, TVSM; Richard Arnold, Executive Director, Norton Motorcycles; Nevijo Mance, Executive Director, Norton Motorcycles Benefiting from investments that have exceeded £200 million into a flagship manufacturing base and company headquarters in Solihull, Norton’s rebirth within the TVS family is a measured and strategic reconstruction of a brand. This Resur
Corpay and National Hockey League Announce Multiyear North American Partnership4.11.2025 15:30:00 EET | Press release
Corpay, Inc.* (NYSE: CPAY), a global leader in corporate payments and the National Hockey League (NHL®) today announced a multiyear North American partnership, naming Corpay’s Cross-Border business the Official Foreign Exchange (FX) Provider of the NHL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104740136/en/ Through this partnership, the NHL will be able to use Corpay Cross-Border’s innovative solutions to help mitigate foreign exchange exposure in their daily operations. The NHL will also benefit from Corpay’s award-winning platform, which allows for seamless global payment management from a single point of access. As part of the partnership, Corpay will have brand presence on the NHL’s digitally enhanced dasherboards and with in-stadium signage at NHL Winter Classic®, NHL Stadium Series™, and NHL Heritage Classic™, in addition to other activation opportunities at NHL tentpole events in future seasons. Corpay and th
Esri Supports IUCN Global Initiative for Nature-Based Education4.11.2025 15:00:00 EET | Press release
At the 2025 IUCN World Conservation Congress, Esri, the global leader in geographic information system (GIS) technology, announced a joint initiative with the International Union for Conservation of Nature (IUCN) and its Commission on Education and Communication to expand access to data, maps, and GIS technology in support of Nature-based Education (NbE) worldwide. Esri is making a $10 million in-kind donation to enable the development of a new NbE geoportal that will allow students, teachers, and IUCN conservationists around the world to understand and explore our planet through maps and the science of geography, collaborate on critical conservation solutions, and develop critical technical skills for future careers in conservation. This new initiative, now in the pilot phase of consultation and design, will support IUCN’s NbE aspirations to promote environmental learning and action as adopted by the Members during the IUCN World Conservation Congress in Abu Dhabi this October. This c
Visa and Transcard Collaborate to Deliver Advanced Embedded Working Capital Solutions in Freight & Logistics4.11.2025 15:00:00 EET | Press release
Visa and Transcard today announced the launch of a next-generation embedded finance platform, designed to power payments and working capital solutions in the freight and logistics industry. As a part of their joint effort, Visa and Transcard are also collaborating on agentic initiatives for the B2B segment. This alliance puts embedded credit and working capital solutions in the hands of freight forwarders and airline carriers on WebCargo by Freightos (Nasdaq: CRGO), a leading digital booking and payments platform in the freight industry. By combining Visa’s global expertise in commercial solutions with Transcard’s leading-edge payment orchestration technology, WebCargo users can now gain access to flexible credit terms, seamless onboarding and automated reconciliation for air cargo transactions. The solution, built on Visa’s virtual card infrastructure, unlocks the cash flow bottlenecks between freight forwarders and airlines, and elevates the digital freight booking and payment experi
Agendia to Present Five Posters Demonstrating the Expanding Clinical Utility of MammaPrint + BluePrint at the 2025 San Antonio Breast Cancer Symposium4.11.2025 14:00:00 EET | Press release
Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new results from the ongoing real-world FLEX Study (NCT03053193) at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place December 9-12 in San Antonio, Texas. The company will present five posters, led by Agendia investigators and independent academic collaborators, that collectively highlight the broad clinical impact of MammaPrint® + BluePrint® genomic profiling in optimizing treatment decisions and improving outcomes for patients with hormone receptor positive, HER2-negative (HR+/HER2–) early breast cancer (EBC). “We look forward to sharing these new findings from the FLEX Study, which spans more than 20,000 participants across 100 global sites, making it the largest and most diverse real-world evidence cohort for early-stage breast cancer,” said William Audeh, M.D., Chief Medical Officer at Agendia. “These results underscore our commitment to generating robust clinical evi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom